drugset
drugset / Trial / NCT04667156

Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects

NCT04667156 ↗

Phase 1 Completed 24 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to investigate relative bioavailability during the new and traditional formulations of SHR6390 in healthy subjects

Timeline

Start
2020-12-13
Primary completion
2021-01-29
Completion
2021-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalpiciclib Small molecule — —

Indications

No indication recorded.